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Abstract We observed that human (Jurkat) T-cells constitu-
tively expressed the mRNA, encoding for the four isoforms
of phospholipase A2 (PLA2), i.e. two secretory (type IB and
type V), and two cytosolic (type IV, Ca2+-dependent and
type VI, Ca2+-independent). In order to assess whether these
PLA2 isoforms are active, we labeled Jurkat T-cells with
[3H]arachidonic acid ([3H]AA) and determined its release into
the extracellular medium in the presence of phorbol 12-myristate
13-acetate (PMA) and ionomycin. The three PLA2 isoforms
seem functional as aristolochic acid and bromoenol lactone
(BEL), the respective inhibitors of type IB/type V and type VI
PLA2s, significantly inhibited the release of free [3H]AA. On the
other hand, arachidonyl trifluoromethyl ketone (AACOCF3), an
inhibitor of type IV PLA2, failed to curtail significantly the
release of free [3H]AA into the extracellular medium. We
assessed the implication of these PLA2 isoforms in transcription
of the interleukin-2 (IL-2) gene, involved in T-cell proliferation.
Hence, aristolochic acid and BEL, but not AACOCF3,
significantly inhibited the PMA and ionomycin-induced induction
of mRNA of IL-2. Similarly, aristolochic acid and BEL, but not
AACOCF3, significantly inhibited the PMA and ionomycin-
induced secretion of IL-2 in the culture supernatants. Together
these results suggest that human Jurkat T-cells possess two
secretory and two cytosolic PLA2 isoforms and only three of
them (type IB, type V and type VI) are implicated in T-cell
proliferation. 6 2002 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
Phospholipase A2 (PLA2, EC 3.1.1.4) represents a class of
enzymes that catalyze the hydrolysis of the sn-2 fatty acyl
bond of phospholipids to give free fatty acids and lysophos-
pholipids [1,2]. These enzymes have been divided into several
groups based on molecular weight, amino acid sequence ho-
mology, calcium dependence and cellular localization [2,3].
There are essentially two large subgroups within the PLA2
family: the small and usually secretory PLA2 (sPLA2) among
which are pancreatic type IB and type V, and the intracellular
cytosolic PLA2 including the well characterized 85 kDa cyto-
solic Ca2þ-dependent type IV PLA2 and the recently cloned
Ca2þ-independent type VI PLA2 [4^6]. During the last decade,
the involvement of distinct types of PLA2 in various biolog-
ical processes has been demonstrated [3,7,8^10]. In particular,
these enzymes have been shown to play a direct role in pro-
liferation of many cell types such as ¢broblasts, stromal and
other cell types [9^12].
T-lymphocytes, antigen-speci¢c cells of the immune system,
are generally quiescent and require antigenic stimulation to
progress from the G0 stage of the cell cycle [13]. Resting
lymphocytes are activated by either aggregation of T-cell re-
ceptor (TCR) with an antigen or mitogen stimulation such as
phorbol 12-myristate 13-acetate (PMA) and ionomycin [14].
The early signaling events, following T-cell activation, include
the activation of protein tyrosine kinases and the phospholi-
pase C pathway to generate intracellular second messengers,
leading to cell proliferation and di¡erentiation [15]. However,
the signaling mechanisms of T-cell activation, especially the
implication of potential lipid second messengers as well as
speci¢c enzyme systems such as PLA2, are not fully eluci-
dated.
For several years, the presence and the role of di¡erent
isoforms of PLA2 in T-cell activation and proliferation have
been controversial [16,17]. Though a Ca2þ-dependent type IV
PLA2 has been shown to be involved in T-cell activation,
neither mRNA nor protein for this PLA2 could be detected
in human T-cells [18]. Hence, the presence of type VI PLA2 in
peripheral blood B- and T-cells and Jurkat T-cells has been
shown [18]. This PLA2 isoform plays a key role in the control
of cell growth [18]. However, the mechanism of action of this
PLA2 isoform remains unknown.
To determine whether one or several PLA2s are involved in
T-cell proliferation, we examined the presence of four di¡er-
ent isoforms of PLA2, i.e. type IB, type V, type IV and type
VI, in Jurkat T-cells. In this investigation, we con¢rmed the
expression of type VI PLA2 and identi¢ed the presence of two
secreted PLA2s (type IB and type V) in Jurkat T-cells where
these isoforms seem to be implicated in cell proliferation.
Moreover, our results revealed, for the ¢rst time, that one
of the targets of these enzymes is the interleukin-2 (IL-2)
gene whose mitogen-induced mRNA expression is down-regu-
lated by the inhibitors of the three PLA2 isoforms.
2. Materials and methods
2.1. Chemicals
Tissue culture medium (RPMI 1640), L-glutamine, penicillin^strep-
tomycin, HEPES and fetal calf serum (FCS) were obtained from Bio-
Whitaker (Verviers, Belgium). The SuperScript II Reverse Transcrip-
tase, Platinum Taq DNA Polymerase, random primers, oligo(dT)18
and the oligonucleotides used as primers in the reverse transcription-
polymerase chain reaction (RT-PCR) analysis were purchased from
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Invitrogene, Life Technologies (Cergy Pontoise, France). Agarose was
from Promega (Charbonnie're, France). Phospholipase A2 inhibitors,
arachidonyl tri£uoromethyl ketone (AACOCF3) and bromoenol lac-
tone (BEL), were from Cayman Chemical (Ann Arbor, USA). Aris-
tolochic acid was from Sigma-Aldrich (Saint Quentin Fallavier,
France). All other chemicals were of analytical grade. The kit (Bender
MedSystem1) for the determination of IL-2 concentrations was pur-
chased from Prolabo (Strasbourg, France).
2.2. Cell culture
For stock culture, Jurkat T-cells were grown in RPMI 1640 medium
supplemented with 10% FCS, 2 mM L-glutamine, 50 Wg/ml penicillin^
streptomycin and 20 mM HEPES at 37‡C in a 95% air^5% CO2
humidi¢ed atmosphere. The medium was changed every 48 h.
For RT-PCR analysis, cells (1.5^2U106) were seeded in six-well
plates and incubated overnight in RPMI 1640 serum-free medium in
order to synchronize them. The cells were then treated or not for 15
min with di¡erent PLA2 inhibitors before stimulation for 2 h with 200
nM PMA and 500 nM ionomycin in RPMI 1640 serum-free medium.
At the end of the experiment, the cells were centrifuged (1500UgU10
min) and the corresponding cell pellet was stored at 380‡C until
RNA extraction.
2.3. RNA isolation and semi-quantitative RT-PCR analysis
Total RNA from cultured Jurkat T-cells was puri¢ed using Trizol
reagent (Invitrogene Life Technologies) according to the manufactur-
er’s instructions.
Oligonucleotide primer pairs, used for mRNA analysis by RT-PCR,
were based on the sequences of the human genes (Table 1). 0.5 Wg of
total RNA was reverse-transcribed at 42‡C for 1 h. The reaction
mixture (10 Wl) containing random hexamer primers (20 pmol), oli-
go(dT)18 primers (10 pmol), 1U reaction bu¡er, deoxynucleoside tri-
phosphate (dNTP, 0.5 mM), SuperScript II Reverse Transcriptase
(100 U) was diluted to 50 Wl with diethyl pyrocarbonate-treated water
at the end of the RT reaction. The cDNA was either used immediately
for PCR or stored at 320‡C until use. For PCR ampli¢cation, a
mixture containing speci¢c oligonucleotide primers (20 pmol), dNTP
(0.2 mM), MgCl2 (12.5 mM) and Platinum Taq DNA Polymerase (0.8
U) was added to 2^10 Wl cDNA (corresponding to 20^100 ng cDNA).
The total volume was increased to 40 Wl with 1U PCR bu¡er. For
PCR ampli¢cation of the gene products, two sets of ampli¢cation
cycles were utilized. In the ¢rst ¢ve cycles, annealing temperature
(4‡C+annealing temperature of the primer) for 5 min was followed
by denaturation temperature (92‡C) for 1 min. In the second set of
ampli¢cation, for 20^30 cycles depending on each PCR-ampli¢ed
product, annealing temperature of the primer for 1 min was followed
by extension temperature (72‡C) for 1 min and another denaturation
temperature (92‡C) for 1 min. The conditions were such that ampli-
¢cation of the product was in the exponential phase, and the assay
was linear with respect to the amount of input cDNA. Human L-actin
mRNA primers were used as internal control to normalize the data.
Reaction products were electrophoresed on a 1% agarose gel impreg-
nated with ethidium bromide. The RNA pattern was visualized by UV
transillumination.
2.4. Arachidonic acid (AA) release
The experiment on AA incorporation and release was performed as
described elsewhere [19]. In brief, Jurkat T-cells were serum-starved
for 4 h before labeling with [3H]AA (1.5 WCi/3U108 cells) for 2 h in
RPMI 1640 serum-free medium supplemented with 0.2% fatty
acid-free bovine serum albumin (BSA). At the end of the incubation,
cells were washed twice with RPMI 1640 serum-free medium contain-
ing 0.2% BSA. The cells were resuspended in 500 Wl RPMI 1640
medium supplemented with 0.5% BSA at a ¢nal concentration of
12U106 cells/ml. Jurkat T-cells were then treated with 5 or 15 WM
of PLA2 inhibitors or vehicle (dimethyl sulfoxide (DMSO), 0.1% ¢nal
concentration) for 30 min, followed by a 20 min stimulation with
PMA (200 nM) and ionomycin (500 nM). Cells were centrifuged
(1250UgU3 min) and 0.4 ml of supernatant was added to 2 ml scin-
tillation cocktail for counting in a liquid scintillation analyzer (Pack-
ard 1900 TR).
2.5. Determination of IL-2 concentrations in culture supernatants
Jurkat T-cells from stock culture were seeded in 25 ml £asks
(2U105 cells/ml) in RPMI 1640 serum-free medium. After overnight
incubation, PLA2 inhibitors (at 5 or 15 WM) or DMSO vehicle (0.1%,
¢nal concentration) were added to cells for 15 min prior to the addi-
tion of PMA (200 nM) and ionomycin (500 nM). The cells were
cultured for 48 h and, after centrifugation (200UgU15 min), the
culture supernatants were saved for the determination of IL-2 concen-
trations. IL-2 concentrations were determined by employing enzyme-
linked immunosorbent assay (ELISA) as per instructions furnished
with the kit (Bender MedSystem1).
Table 1
Sequences of primers of IL-2 and di¡erent PLA2 isoforms
Gene Primer sequences Expected size (bp)
PLA2-IB S 5P-CGTGTCGCAGTTCCGCAAAATGAT-3P 240
AS 5P-GCCGACCCAGAGCACGAGTATGAA-3P
PLA2-V S 5P-TGGCTTGGTTCCTGGCTTCTTGTAGTG-3P 211
AS 5P-TTCTCCTCCAGCCGCCCATAGCAG-3P
PLA2-IV S 5P-CCCAAAGGCACTGAAAATGAAGAT-3P 347
AS 5P-GGGATACGGCAGGTTAAATGTGAG-3P
PLA2-VI S 5P-GCAGCGCCACATCATCCCTTCTCC-3P 271
AS 5P-TGCCCGCCACCCAGTCAAACAG-3P
IL-2 S 5P-CACTAATTCTTGCACTTGTCAC-3P 186
AS 5P-CCTTCTTGGGCATGTAAAACT-3P
L-Actin S 5P-ATGATATCGCCGCGCTCGTCGTC-3P 547
AS 5P-AGGTCCCGGCCAGCCAGGTCCAG-3P
Fig. 1. Constitutive expression of di¡erent PLA2 isoforms in Jurkat
T-cells. Quiescent Jurkat T-cells were treated for 2 h with or with-
out PMA (200 nM) and ionomycin (500 nM). Total RNA was iso-
lated and analyzed by RT-PCR using speci¢c primers for human
PLA2-IB, -V, -IV and -VI as described in Section 2. L-Actin mRNA
was used as an internal standard. One representative blot of three
independent experiments is shown.
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2.6. Statistical analysis
Results are shown as meanRS.E.M. Statistical analysis of data was
carried out using Statistica (version 4.1, Statsoft, Paris, France). The
signi¢cance of the di¡erences between mean values was determined by
analysis of variance one way, followed by a least signi¢cant di¡erence
test.
3. Results
3.1. PLA2s of type-IB, -V, -IV and -VI are constitutively
expressed in Jurkat T-cells
To shed light on whether the Jurkat T-cells expressed or not
PLA2 mRNA, we designed speci¢c primers directed against
four di¡erent PLA2 isoforms (Table 1). Two secreted PLA2s
(type IB and V) as well as two cytosolic PLA2s (type IV Ca2þ-
dependent and type VI Ca2þ-independent) were selected. As
shown in Fig. 1, these four PLA2 isoforms were constitutively
expressed in quiescent Jurkat T-cells. As these PLA2s were
shown to be involved in cell proliferation, we examined the
e¡ect of a mitogenic signal on the mRNA expression of these
isoforms. Jurkat T-cells were stimulated for 2 h with PMA
and ionomycin and the expression of di¡erent PLA2 isoforms
was measured by semi-quantitative RT-PCR. The results dem-
onstrated that none of these PLA2 isoforms were regulated at
the mRNA level after the mitogenic stimulation (Fig. 1).
3.2. Release of [3H]AA is inhibited by secreted and cytosolic
Ca2+-independent PLA2 inhibitors in Jurkat T-cells
To determine whether these enzymes were active in Jurkat
T-cells, we examined the release of [3H]AA after stimulation
by PMA and ionomycin in the presence of di¡erent PLA2
inhibitors. The results showed that aristolochic acid, a non-
speci¢c inhibitor of type IB/V sPLA2 and BEL, an inhibitor of
cytosolic and Ca2þ-independent type VI PLA2, were able to
signi¢cantly decrease [3H]AA release, induced by PMA and
ionomycin (Fig. 2). AACOCF3, an inhibitor of cytosolic
Ca2þ-dependent type IV PLA2 exerted no signi¢cant e¡ect
on [3H]AA release in these cells. In control cells (vehicle con-
trol), no signi¢cant release of [3H]AA was observed (results
not shown).
3.3. IL-2 mRNA expression, induced by PMA and ionomycin,
is inhibited by secreted and Ca2+-independent PLA2
inhibitors
To study the mechanism of action of PLA2 on T-cell pro-
liferation, we ¢rst designed the primers of IL-2 and L-actin
mRNA (Table 1) and examined the kinetic of expression of
IL-2 mRNA after PMA and ionomycin stimulation; IL-2
Fig. 2. E¡ect of PLA2 inhibitors on [3H]AA release. Serum-starved Jurkat T-cells (3U108) were labeled for 2 h with 1.5 WCi [3H]AA. The cells
were then treated with 5 or 15 WM AACOCF3, aristolochic acid or BEL or with vehicle (DMSO, 0.1% ¢nal concentration) for 30 min,
followed by a 20 min stimulation with PMA (200 nM) and ionomycin (500 nM) (PMA and IONO). Cells were harvested as described in Sec-
tion 2. Results are expressed as meanRS.E.M. of three independent experiments. Data are expressed as a percentage of PMA- and iono-
mycin-stimulated cells which was considered to be 100%. Data are signi¢cantly di¡erent as compared to PMA and IONO group (*P6 0.001).
NS represents insigni¢cant values.
Fig. 3. Kinetics of IL-2 mRNA expression after PMA and ionomy-
cin stimulation. Harvested Jurkat T-cells were cultured for di¡erent
times in RPMI 1640 serum-free medium with PMA (200 nM) and
ionomycin (500 nM). RNA was prepared and subjected to semi-
quantitative RT-PCR analysis as described in Section 2. PCR prod-
ucts were visualized by UV transillumination. A representative blot
(n=3) is shown.
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being one of the ¢rst genes expressed during the early events
of T-cell activation and proliferation. Fig. 3 showed that no
IL-2 mRNA was detectable in quiescent Jurkat T-cells ; how-
ever, the cells started to express IL-2 mRNA after 1 h of
treatment with PMA and ionomycin. Maximum IL-2 levels
were obtained after 2 h of stimulation. We treated T-cells
with either AACOCF3, aristolochic acid or BEL and exam-
ined IL-2 mRNA expression after 2 h of PMA and ionomycin
treatment (Fig. 4). AACOCF3 failed to curtail the expression
of IL-2 mRNA induced by PMA and ionomycin, though
aristolochic acid and BEL completely abolished this induction
(Fig. 4).
3.4. IL-2 secretion, stimulated by PMA and ionomycin, is
inhibited by secreted and Ca2+-independent PLA2
inhibitors
To con¢rm the role of these PLA2s in T-cell proliferation,
Jurkat T-cells were stimulated by PMA and ionomycin with
AACOCF3, aristolochic acid or BEL. After 48 h of stimula-
tion, culture supernatants were used for the determination of
secreted IL-2. We observed that only aristolochic acid and
BEL were able to signi¢cantly inhibit the secretion of IL-2,
induced by PMA and ionomycin (Fig. 5). AACOCF3 exerted
mild, but insigni¢cant, e¡ect on IL-2 secretion in the stimu-
lated T-cells (Fig. 5).
Fig. 4. E¡ect of di¡erent PLA2 inhibitors on the induction of IL-2 mRNA levels by PMA and ionomycin. Jurkat T-cells were pre-treated for
15 min with (5 or 15 WM) AACOCF3 (A), aristolochic acid (B) and BEL (C) before a 2 h stimulation with PMA (100 nM) and ionomycin
(500 nM). Total RNA was prepared and subjected to RT-PCR analysis as described in Section 2. The left panel shows a representative blot
(n=3) and the right panel depicts the normalized mRNA levels (meanRS.E.M.), values are expressed as a percentage of the control which was
considered 100%). Data are signi¢cantly di¡erent as compared to PMA- and ionomycin-stimulated cells (*P6 0.001).
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4. Discussion
In the present study, we have observed that Jurkat T-cells
constitutively express mRNA encoding for four di¡erent
PLA2 isoforms (type-IB, -V, -IV and -VI) among which se-
creted (type IB and type V) as well as cytosolic Ca2þ-indepen-
dent (type VI) PLA2s appear to play a critical role in T-cell
proliferation.
Though some cell types of the immune system, like murine
macrophages and mast cells, have been reported to possess
functional sPLA2 type V, the lymphocytes do not seem to
possess this sPLA2 isoform [15,20]. However, our study on
the expression of mRNA of type VI PLA2 as well as type V
PLA2 in Jurkat T-cells is consistent with a recent report in
which human peripheral blood T- and B-lymphocytes and
Jurkat T-cells have been demonstrated to possess these
PLA2 isoforms [18]. We should recall that the existence of
mRNA for 85 kDa PLA2 and its protein has been reported
in activated thymocytes and immature B-cells ; however, this
isoform of PLA2 has been found to be absent and the expres-
sion of its mRNA could not be induced in mature T- and
B-cells [18,21]. On the contrary, in the present report, only
low, but detectable, mRNA levels of this isoform of PLA2
(type IV) in Jurkat cells are noticed. Our results are in agree-
ment with the ¢ndings of Boilard and Surette [17] who have
recently identi¢ed type IV PLA2 in human T-lymphocytes.
In the present report, we demonstrate, for the ¢rst time, the
expression of mRNA of type IB PLA2 in Jurkat T-cells. To
date, expression of this PLA2 isoform, which was ¢rst discov-
ered in pancreatic juice, then in several cell types and tissues,
has never been shown in T-lymphocytes [22,23].
In order to gain insight into the functional implication of
di¡erent PLA2 isoforms, we employed their inhibitors and
conducted studies, at ¢rst hand, on the release of [3H]AA.
We used aristolochic acid, an inhibitor of sPLA2 and
AACOCF3, an inhibitor of 85 kDa PLA2, including type IV
[24]. We also employed BEL, a mechanism based inhibitor,
used to inhibit the cytosolic Ca2þ-independent PLA2 [25]. We
have observed that aristolochic acid and BEL, but not
AACOCF3, inhibited signi¢cantly PMA- and ionomycin-
stimulated release of AA into extracellular environment. In
order to ascertain whether PLA2 inhibitors diminish the tran-
scription of IL-2 gene, we assessed the e¡ects of these inhib-
itors on mitogenic expression of IL-2 mRNA. As anticipated,
aristolochic acid and BEL, but not AACOCF3, inhibited the
PMA and ionomycin-induced expression of IL-2 mRNA.
Similarly, the two PLA2 inhibitors, aristolochic acid and
BEL, but not AACOCF3, signi¢cantly inhibited the PMA-
and ionomycin-stimulated secretion of IL-2 in the culture
supernatants. In these experiments, AACOCF3 mildly cur-
tailed IL-2 secretion and this inhibitory e¡ect can be explained
by the fact that this PLA2 inhibitor, being present for 48 h in
the culture medium, might exert its e¡ect non-speci¢cally on
cytosolic Ca2þ-independent PLA2 as suggested by Anderson
et al. [26]. These observations altogether suggest that human
Jurkat T-cells express the mRNA encoding for two secretory
and two cytosolic (Ca2þ-independent and Ca2þ-dependent)
isoforms of PLA2 and only the three species (two secretory
and one cytosolic Ca2þ-independent) are implicated in T-cell
blastogenesis.
The exact mechanisms of action of PLA2s in the inhibition
of IL-2 secretion, considered as an indicator of T-cell prolif-
eration, is not known. We can speculate that T-cell activation
via TCR may be coupled to PLA2 activation as observed by
Bouilard and Surette [17] that anti-CD3 antibodies induced
TCR signalling and phosphorylation of a type IV PLA2 in
Fig. 5. E¡ect of di¡erent PLA2 inhibitors on IL-2 secretion in the culture supernatants. Jurkat T-cells (2U105 cells/ml) were treated with (5 or
15 WM) AACOCF3, aristolochic acid or BEL or with DMSO vehicle (0.1%) alone for 15 min prior to a stimulation with 200 nM PMA and
500 nM ionomycin (PMA and IONO) in RPMI 1640 serum-free medium. After 48 h, the cells were centrifuged (200UgU15 min) and the cul-
ture supernatants were used for the determination of IL-2 concentrations by ELISA, according to the instructions furnished with the kit (Ben-
der MedSystem1). Data represent meanRS.E.M. of quadruple independent experiments. Data are signi¢cantly di¡erent as compared to vehicle
control (*P6 0.001) and as compared to PMA- and ionomycin-treated groups (**P6 0.001). NS represents insigni¢cant values as compared to
the PMA- and ionomycin-treated groups.
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human T-cells. Furthermore, the importance of PLA2 in
T-cell proliferation has also been shown by Kudo et al. [27]
as these investigators have observed that addition of exoge-
nous PLA2 to human T-cells can greatly enhance the signal-
induced cell activation [27]. Nonetheless, we can speculate
that released free AA, as observed in our study, may act in
an autocrine manner to accelerate T-cell blastogenesis. Hence,
we can envisage per se e¡ects of free AA on cell signalling as
Jurkat T-cells do not possess the enzymes that can metabolize
the free fatty acids into eicosanoids [28,29]. We have recently
shown that free fatty acids modulate calcium signaling and
mitogen activated protein kinase activation in Jurkat T-cells
[30^32]. Alternatively, free AA, in place of being released to
the extracellular environment, may be translocated to the nu-
cleus as it has been observed in a stromal cell line [33]. Nu-
clear AA may directly a¡ect the transcription of several genes
via PPARQ whose implication in T-cell proliferation has been
recently documented [34]. PLA2 may also regulate lymphocyte
phospholipid turnover in coordination with lysotransferase
enzymes.
Other products of PLA2-induced hydrolysis of phospholip-
ids are lysophospholipids [1,2]. The lysophospholipids like
lyso-phosphatidylcholine have been found to be co-activators
of protein kinase C (PKC), implicated in T-cell proliferation
[35]. For instance, lyso-phosphatidylcholine per se is toxic for
human T-cells but in the presence of endogenous diacylglycer-
ol, this agent stimulates several fold the activation of PKC,
implicated in Jurkat T-cell proliferation [32,35]. It is also pos-
sible that PLA2 inhibitors diminish, in part, T-cell prolifera-
tion, by diminishing the production of lysophospholipids.
In our study, the use of di¡erent PLA2 inhibitors allowed
us to show that three enzymes are functional and play a cru-
cial role in T-cell activation. These results open the door to
the synthesis of more potent PLA2 inhibitors that will bear
immunosuppressive properties and can be used in immuno-
therapy of autoimmune diseases.
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